Amneal Pharmaceuticals Inc (AMRX)
8.19
-0.16
(-1.92%)
USD |
NASDAQ |
Sep 27, 16:00
8.19
0.00 (0.00%)
After-Hours: 20:00
Amneal Pharmaceuticals Cash from Financing (Quarterly): -35.09M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -35.09M |
| March 31, 2024 | -23.16M |
| December 31, 2023 | -100.83M |
| September 30, 2023 | -86.58M |
| June 30, 2023 | -12.26M |
| March 31, 2023 | -12.90M |
| December 31, 2022 | -22.17M |
| September 30, 2022 | -46.13M |
| June 30, 2022 | 23.25M |
| March 31, 2022 | -61.57M |
| December 31, 2021 | -30.35M |
| September 30, 2021 | -43.56M |
| June 30, 2021 | -38.07M |
| Date | Value |
|---|---|
| March 31, 2021 | -26.15M |
| December 31, 2020 | -11.28M |
| September 30, 2020 | -14.81M |
| June 30, 2020 | -310.08M |
| March 31, 2020 | 467.98M |
| December 31, 2019 | -7.298M |
| September 30, 2019 | -7.596M |
| June 30, 2019 | -9.075M |
| March 31, 2019 | -21.86M |
| December 31, 2018 | -218.92M |
| September 30, 2018 | 82.60M |
| June 30, 2018 | 457.24M |
| March 31, 2018 | -33.25M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-310.08M
Minimum
Jun 2020
467.98M
Maximum
Mar 2020
-19.93M
Average
-24.65M
Median
Cash from Financing (Quarterly) Benchmarks
| Eli Lilly and Co | 1.556B |
| Amphastar Pharmaceuticals Inc | -10.72M |
| Nutriband Inc | -0.0051M |
| NovaBay Pharmaceuticals Inc | -0.492M |
| Palatin Technologies Inc | 9.136M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 39.66M |
| Cash from Investing (Quarterly) | -6.465M |
| Free Cash Flow | 176.08M |
| Free Cash Flow Per Share (Quarterly) | 0.0884 |
| Free Cash Flow to Equity (Quarterly) | 47.37M |
| Free Cash Flow to Firm (Quarterly) | 82.27M |
| Free Cash Flow Yield | 8.35% |